Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Institutional Evaluation of C2i-Test Performance for Detecting Molecular Residual Disease (MRD) in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy.

NCT05860543 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT05860543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05860543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Institutional Evaluation of C2i-Test Performance for Detecting Molecular Residual Disease (MRD) in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy.
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Observational
Overall status
Withdrawn
Start date
August 31, 2024
Completion date
June 1, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder cancer